Primary Care Reports – January 1, 2006
January 1, 2006
View Issues
-
Pharmacology Watch
FDA Recommends Approval of Muraglitazar, But May Need To Reconsider; Which Antipsychotics Are More Dangerous?; Should CPOE Undergo Evaluation?; New Treatment for Tennis Elbow; FDA Actions -
Clinical Briefs in Primary Care supplement
-
Prostate Cancer Screening Part I: The Screening Dilemma, Screening Tests, and the Role of Prostate Specific Antigen Testing
Prostate cancer is one of the leading causes of cancer in men, both in this country and in Europe. Due to the introduction of the prostate specific antigen blood test (PSA test), the ability to diagnose prostate cancer well before signs or symptoms of the disease develop has been realized. Following its introduction, the PSA was endorsed widely and recommended by many major public health organizations as a useful screening test.